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Primary pulmonary hypertension carries a poor prog•
nosis, with a 5 year survival rate of less than 25 % • 
However, a previous study of more than 100 patients 
with tissue-proved primary pulmonary hypertension 
suggested that anti thrombotic therapy may have a ben•
eficial effect on survival, especially in patients with the 
thromboembolic type of primary pulmonary hyperten•
sion. This report describes a 54 year old white man with 
primary pulmonary hypertension of the thromboembolic 
type (proved by right upper lobe lung biopsy) who, after 
long-term antithrombotic therapy, showed resolution of 
symptoms of dyspnea and fatigue, regression of electro•
cardiographic signs of right ventricular hypertrophy and 
regression of elevated pulmonary artery pressure. Base•
line cardiac catheterization in January 1982 revealed 
Primary pulmonary hypertension carries a poor prognosis. 
A recent study by Steele, Fuster and their coworkers (1,2) 
in 120 patients with primary pulmonary hypertension fol•
lowed up for at least 5 years indicated that only 21 % of the 
patients were alive 5 years after the initial diagnosis. How•
ever, several reports (3-9) of individuals or small groups 
of patients have suggested benefit from vasodilator therapy 
or spontaneous improvement. In addition, there is one report 
(10) of a patient whose condition improved dramatically 
with antithrombotic therapy. Unfortunately, none of these 
case reports correlated the response to the specific inter•
vention with pathologic findings. This report documents 
relief of symptoms and regression of severe pulmonary hy•
pertension during anti thrombotic therapy in a patient dem•
onstrated by open lung biopsy to have primary pulmonary 
hypertension of the thromboembolic type (World Health 
Organization classification [11]). 
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elevated pulmonary artery pressure (104/37 mm Hg) and 
pulmonary vascular resistance (14.6 units/m2) that did 
not decrease with 100% oxygen or intravenous hydral•
azine (12 mg). The patient was treated with warfarin 
and dipyridamole, 100 mg four times daily. The most 
recent cardiac catheterization in January 1984 revealed 
a pulmonary artery pressure of 50/15 mm Hg and a 
pulmonary vascular resistance of 8.7 units/m2• 
It is believed that this is the first report of regression 
of the symptoms and signs of biopsy-proved primary 
pulmonary hypertension. In view of the lack of a re•
sponse to vasodilators in 1982, it is suggested that an•
tithrombotic therapy is partially responsible for the im•
provement of this patient. 
(J Am Coli CardioI1986;7:172-5) 
Case Report 
Clinical features. A 54 year old white male business 
manager was in excellent health until May 1981, when he 
noticed progressive dyspnea on exertion and easy fatiga•
bility. A brother had died from systemic lupus erythema•
tosus involving the kidneys, and a niece has scleroderma. 
The patient denied any history of cigarette smoking, inges•
tion of appetite suppressants, exposure to pulmonary irri•
tants or symptoms of Raynaud's phenomenon, but admitted 
to taking vitamin C, 3 to 5 g daily, from 1975 to the time 
of presentation. 
Physical examination in December 1981 revealed a well 
developed, acyanotic man with a blood pressure of 130/90 
mm Hg, a heart rate of 70 beats/min and a respiration rate 
of 16 breaths/min. There was no neck vein distension, and 
the lungs were clear to percussion and auscultation. Cardiac 
examination revealed normal splitting of the second heart 
sound, but the pulmonary component was increased in in•
tensity. In addition, there was a right ventricular fourth 
sound gallop and an ejection click heard best in the pul•
monary region. No peripheral edema was observed, and the 
rest of the examination was unremarkable. 
Hemoglobin was 17 g/dl, and serum electrolytes and 
complete blood count were within normal limits. Chest x-
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Table 1. Serial Hemodynamic Data During 21/2 Years of Antithrombotic Therapy 
December January 
January 1982 1982 1984 
Rest 100% Oxygen Hydralazine* Rest Rest 
Heart rate (beats/mm) 90 85 85 80 75 
Pulmonary artery 104137 94/38 87137 60/20 50115 
pressure (mm Hg) 
Pulmonary capillary 10 6 6 
wedge pressure (mm Hg) 
Mean pulmonary artery 60 56 54 40 26 
pressure (mm Hg) 
Cardiac index (liters/mm per m2) 4.1 35 4.3 3.0 30 
Total pulmonary 14.6 16.0 12.6 133 8.7 
resistance (umts/m2) 
ElectrocardIogram RAD.RVH WNL WNL 
*Refers to hydralazine, 0.15 mg/kg intravenously. RAD = right axis deviatIOn; RVH = right ventncular 
hypertrophy; WNL = within normal limits. 
ray examination at this time suggested right ventricular 
prominence with proximal pulmonary artery enlargement. 
The electrocardiogram revealed normal sinus rhythm, right 
axis deviation and right ventricular hypertrophy with strain. 
Tests for antinuclear antibodies, latex fixation, impedance 
plethysmography of the lower limbs and the ventilation•
perfusion lung scan were all negative. 
Right and left heart catheterization performed in January 
1982 (Table 1) revealed: 1) normal left ventricular function 
and normal coronary arteries, 2) no evidence of left to right 
shunt. and 3) severe pulmonary hypertension. An arterial 
blood gas determination at room air showed a Pao2 of 60 
mm Hg, Paco2 of35 mm Hg and pH of7.43. No significant 
reduction of the pUlmonary vascular resistance occurred with 
either 100% inspired oxygen or intravenous hydralazine (0.15 
mg/kg body weight). 
Open lung biopsy performed in February 1982 (Fig. 1) 
revealed severe luminal obstruction by eccentric intimal pro•
liferation and focal early recanalization consistent with or•
ganization of thrombotic material. There were no plexiform 
'1 
Figure 1. Photomicrographs of open lung biopsy 
specimen, showing severe luminal obstruction by 
eccentric intimal proliferation (A through D) and 
focal early recanalization (8 and C) consistent with 
organization of thrombotic material. (A, Elastic-van 
Gieson stain, X 35; 8 through D, hematoxylin-eosin 
stain, X 90.) 
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or dilation lesions and no necrotizing arteritis. Pulmonary 
veins and lymphatic channels were normal, and there was 
no hemosiderosis. 
Treatment. Because there were no clinical signs or lab•
oratory tests indicative of recurrent pUlmonary embolism, 
a diagnosis of primary pulmonary hypertension of the throm•
boembolic type was made. The patient was advised to stop 
ingestion of vitamin C and begin therapy with warfarin (to 
maintain the prothrombin time at twice the normal level) 
and dipyridamole, 100 mg four times daily. 
Follow-up. Over the course of the next 2Y2 years, the 
patient experienced relief of symptoms of exertional dys•
pnea and fatigue. In addition, an electrocardiogram in Feb•
ruary 1984 revealed a normal axis and no signs of right 
ventricular hypertrophy. Serial right heart catheterizations 
revealed a progressive decrease in pulmonary artery pressure 
and total pulmonary vascular resistance (Table 1). The pa•
tient is now working full time and is asymptomatic, even 
on strenuous exertion. 
Discussion 
The treatment for patients with severe pulmonary hy•
pertension is, in general, disappointing. Small series of pa•
tients with pulmonary hypertension secondary to docu•
mented recurrent pulmonary embolism who showed 
improvement after surgical embolectomy have been de•
scribed (12,13). To our knowledge, however, regression of 
pUlmonary hypertension in this condition with medical ther•
apy alone has not been reported. The experience with severe 
pUlmonary hypertension secondary to primary pulmonary 
hypertension is similar. 
Despite several case reports (14) describing dramatic im•
provement after therapy, the overall prognosis for patients 
with primary pUlmonary hypertension is poor. Discovery of 
an effective therapy will probably evolve after the causes 
of this disease are better understood, and after diagnosis 
becomes possible earlier in its course. On the basis of the 
classic studies of Wagenvoort et al. (15), the World Health 
Organization (11) has classified primary pUlmonary hyper•
tension into three histopathologic types: 1) plexogenic ar•
teriopathy, 2) thromboembolic, and 3) veno-occlusive. The 
thromboembolic and veno-occlusive types do not exhibit 
plexiform lesions. Together with these observations, more 
recent investigations (2,16,17) suggest that at least two path•
ogenetic mechanisms may have a role in primary pulmonary 
hypertension. In some patients, pathologic data suggest a 
thromboembolic mechanism in either the small pulmonary 
arteries or veins; in other patients, they suggest a vasocon•
strictive mechanism. Many reports (3-8) have indicated that 
therapy with drugs known to reverse vasoconstriction may 
result in lessening of symptoms and improvement in pul•
monary hemodynamics at rest and during exercise. These 
reports described individuals or small groups of patients, 
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and the follow-up period was usually relatively short. Wilken 
et al. (10) documented in one patient dramatic relief of signs 
and symptoms of primary pulmonary hypertension during 
antithrombotic therapy. In addition, Steele, Fuster and their 
coworkers (1,2) demonstrated that anti thrombotic therapy 
was associated with a significant improvement in survival. 
None of these reports, however, documented a regression 
of pulmonary hypertension in a patient with biopsy-proved 
primary pUlmonary hypertension. 
Our case report documents the relief of symptoms and 
regression of severe pulmonary hypertension during anti•
thrombotic therapy in a patient demonstrated by open lung 
biopsy to have primary pulmonary hypertension of the 
thromboembolic type. Because we are not aware of any 
known relation between vitamin C and primary pulmonary 
hypertension, we consider it unlikely that vitamin C pre•
cipitated the pulmonary hypertension or that its withdrawal 
was responsible for the patient's recovery. In addition, it is 
doubtful that the vasodilatory action of dipyridamole is re•
sponsible for his improvement in view of the lack of a 
response to either 100% oxygen or hydralazine (in 1982). 
It is our belief, therefore, that antithrombotic therapy is 
partially responsible for the patient's improvement. 
This case highlights how a combined approach of cardiac 
catheterization and drug testing together with open lung 
biopsy allows the physician to identify the most rational 
therapy. In view of the generally grim prognosis of primary 
pulmonary hypertension, the insights gained from these in•
vasive procedures, especially for patients who are seen early 
in the course of their disease, may outweigh the risks. 
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